在ALTA-1L试验中,在前线布里加替尼之后,现实世界的治疗模式和随后的治疗有效性
Myung-Ju Ahn1, Angelo Delmonte2, Sharmistha Ghosh3
1Division of Hematology, Oncology Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, South Korea.
现实数据显示,在布里加替尼治疗后,患者继续服用ALK氨酸激酶抑制剂 (TKIs),经历了长时间的益处. 第二代或第三代ALK TKIs在随后的治疗线路中显示出显著的临床优势.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 布里加替尼 (Brigatinib) 是对非小细胞肺癌 (NSCLC) 的第一线治疗.
- 了解布里加替尼停药后的现实结果对于优化后续治疗策略至关重要.
研究的目的:
- 为了评估在停止治疗后在ALTA-1L试验中接受布里加替尼治疗的患者的现实结果.
- 评估二线 (2L) 治疗的疗效,包括ALK氨酸激酶抑制剂 (TKI) 和非ALK TKI.
主要方法:
- 从ALTA-1L试验中对布里加替尼停药后患者的回顾性图表审查.
- 对2L疗法的现实整体响应率 (rwORR),终止治疗的时间 (rwTTD) 和无进展生存率 (rwPFS) 的分析.
主要成果:
- 30名患者接受了2L ALK TKIs (洛拉提尼布,阿莱克提尼布),达到33%的rwORR和16.1个月的2L rwPFS中位数.
- 2L rwTTD的中位数为ALK TKIs的34.7个月,比非ALK TKIs (4.4个月) 长得多.
- 洛拉提尼布和阿莱克提尼布在2L环境中表现出有希望的结果.
结论:
- 大多数患者在停止布里加替尼治疗后开始第二次ALK TKI.
- 治疗二代或第三代ALK TKIs后布里加替尼与延长的临床益处有关.
- 现实世界的数据支持在布里加替尼治疗进展的患者中使用随后的ALK TKIs.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
